The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease

Second Affiliated Hospital, Zhejiang University, School of Medicine166 enrolled

Overview

The IFX adherence to CD in China was not high. Medicine concerns may be predictive factor of adherence. By enhancing knowledge and relieving medicine concerns, we may increase patients' adherence to IFX.

Crohn's disease (CD) is an incurable chronic disease that requires long-term treatment. As an anti-tumor necrosis factor (TNF) agent, Infliximab (IFX) is widely used in the treatment of Crohn's disease, while the adherence is not high. The purpose of this study was to investigate the adherence to IFX among CD patients in China and evaluate the association between medication belief and IFX adherence.

Study Type

OBSERVATIONAL

Enrollment

166

Conditions

Inflammatory Bowel Diseases

Eligibility

Sex: ALLMin age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with a confirmed diagnosis of CD; were treated with infliximab for at least 12 weeks; were informed consent. Exclusion Criteria: * The exclusion criteria were received treatment from mental health professionals due to any mental or cognitive impairment; suffered from other serious diseases, such as heart, brain, lung, liver and kidney dysfunction; severe infection, anemia, cachexia or other serious complications were found.

Locations (1)

2ndAffiliated Hospital, School of Medicine, Zhejiang University, China

Zhejiang, China

Outcomes

Primary Outcomes

Adherence

Adherence was judged by comparing the theoretical infusion times with the actual infusion times in recent 1 year, which was referred to the definition of modified medication possession radio (mMPR)

Time frame: November 15 to December 28, 2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.